Gleason score predicts androgen independent progression after androgen deprivation therapy

被引:54
作者
Benaim, EA
Pace, CM
Roehrborn, CG
机构
[1] Univ Texas, SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[2] N Texas Vet Adm Hlth Care Ctr, Dallas, TX 75390 USA
关键词
prostatic neoplasm; tumor markers; biological neoplasms; hormone-dependent therapy; androgen antagonists; castration; male;
D O I
10.1016/S0302-2838(02)00238-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective: The Gleason system is the most widely utilized histologic grading system for prostate cancer and a powerful predictor of cancer behavior. In this study, we evaluated the prognostic value of the Gleason grading system in predicting progression to androgen independent prostate cancer (AIPC). Methods: Records from 150 patients with advanced or metastatic prostate cancer treated with androgen deprivation therapy (ADT) were retrospectively reviewed. Androgen independent progression was defined as two consecutive elevations of serum prostate specific antigen (PSA) above the nadir value. Kaplan-Meier and the Cox proportional hazards methods were used to assess potential predictors of progression to AIPC. Results: Patients with low and moderate Gleason scores experienced significantly longer remissions compared to those with Gleason score of 8-10 (p=0.0006, Log-Rank test). The cumulative hazard of progressing to AIPC increased by almost 70% for each unit increase in total Gleason score. Conclusion: In this patient cohort the Gleason score was the only independent predictor of progression to AIPC.
引用
收藏
页码:12 / 17
页数:6
相关论文
共 21 条
[1]
Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Gleason, DF ;
Barry, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :975-980
[2]
INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGE-D2) PROSTATE-CANCER [J].
CHODAK, GW ;
VOGELZANG, NJ ;
CAPLAN, RJ ;
SOLOWAY, M ;
SMITH, JA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (05) :618-621
[3]
THE ROLE OF WATCHFUL WAITING IN THE MANAGEMENT OF LOCALIZED PROSTATE-CANCER [J].
CHODAK, GW .
JOURNAL OF UROLOGY, 1994, 152 (05) :1766-1768
[4]
COOPER EH, 1990, CANCER, V66, P1025
[5]
CRAWFORD ED, 1990, CANCER-AM CANCER SOC, V66, P1039
[6]
A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].
CRAWFORD, ED ;
EISENBERGER, MA ;
MCLEOD, DG ;
SPAULDING, JT ;
BENSON, R ;
DORR, FA ;
BLUMENSTEIN, BA ;
DAVIS, MA ;
GOODMAN, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424
[7]
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[8]
Maximal androgen blockade: Final analysis of EORTC phase III trial 30853 [J].
Denis, LJ ;
Keuppens, F ;
Smith, PH ;
Whelan, P ;
de Moura, JLC ;
Newling, D ;
Bono, A ;
Sylvester, R .
EUROPEAN UROLOGY, 1998, 33 (02) :144-151
[9]
EISENBERGER MA, 1994, SEMIN ONCOL, V21, P613
[10]
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer [J].
Eisenberger, MA ;
Blumenstein, BA ;
Crawford, ED ;
Miller, G ;
McLeod, DG ;
Loehrer, PJ ;
Wilding, G ;
Sears, K ;
Culkin, DJ ;
Thompson, IM ;
Bueschen, AJ ;
Lowe, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (15) :1036-1042